By injecting sRANKL, novel osteopenia model mice were established in only 50 hours.
Degree of bone loss can be controlled by changing doses of sRANKL
High Activity and low endotoxin level.
sRANKL can be used in establishing osteopenia model for in vivo screening of drugs for osteoporosis, determination of effect and mechanism, evaluation of bone anabolic drugs.